The objective of this post hoc analysis of the Phase 2 trial was to assess the effect of BMS-986165 on in the pathogenesis of psoriasis and other immune-mediated disorders \(^1\)–\(^5\). TYK2 activates intracellular signal transducer and activator of transcription (STAT)-dependent signaling of the 12-week treatment period.

Mean (standard deviation [SD]), median (interquartile range), or median (range) absolute values for metabolic parameters (creatinine, creatine phosphokinase [CPK], glucose, total cholesterol, high-density lipoprotein cholesterol [HDL-C], and lipoprotein(a) [Lp(a)]) were compared between placebo and BMS-986165 treatment groups.

For all randomized and treated patients who received BMS-986165 3 mg BID, 6 mg BID, or 12 mg QD or placebo, changes in CPK levels were not dose-dependent and there were no events resulting in discontinuation by Bristol-Myers Squibb Company.

**References**


**Conclusions**

- There were no consistent differences observed between placebo and BMS-986165 treatment groups in any hematological parameter, serum chemistry (hepatic, renal, or lipid) parameters, or any vital sign metric.

- In addition, there were no clear dose-dependent changes observed with BMS-986165 for any of the laboratory parameters investigated.

- Results of 2 large ongoing Phase 3 trials of BMS-986165 (NCT03611751 [POETYK-PSO-2], NCT03466500 [POETYK-PSO-3], and NCT03924427) and the long-term extension study (NCT03804403) in patients with moderate to severe plaque psoriasis will provide long-term safety and laboratory data.

## Methods

**Laboratory assessments**

- Assessments of clinical laboratory parameters included hematologic parameters, C-reactive protein, creatine phosphokinase, total cholesterol, high-density lipoprotein cholesterol (HDL-C), and lipoprotein(a) levels, and absolute neutrophil and lymphocyte counts.

- There were no consistent differences observed between placebo and BMS-986165 treatment groups in any hematological parameter, serum chemistry (hepatic, renal, or lipid) parameters, or any vital sign metric.

- In addition, there were no clear dose-dependent changes observed with BMS-986165 for any of the laboratory parameters investigated.

- Results of 2 large ongoing Phase 3 trials of BMS-986165 (NCT03611751 [POETYK-PSO-2], NCT03466500 [POETYK-PSO-3], and NCT03924427) and the long-term extension study (NCT03804403) in patients with moderate to severe plaque psoriasis will provide long-term safety and laboratory data.

## Acknowledgments

- The authors are grateful to the patients who participated in the studies described here.

- The authors also thank the study investigators and their participating centers.

- The study described here was supported by the U.S. National Institutes of Health (NIH) under grants R01 AI132861 and R01 AI121566 (to G.M.) and the Intramural Research Program of the NIH, National Institute of Diabetes, Digestive and Kidney Diseases.

- The authors thank the biostatisticians at Bristol Myers Squibb (Princeton, NJ) for data management and statistical analysis.

- The authors also thank the Bristol Myers Squibb Clinical Operations staff for their support.

- The authors declare no conflict of interest.

**Relationships and Activities**

- BR: Research support/principal investigator (clinical trials): AbbVie, Almirall, Amgen, Biogen Idec, Boehringer Ingelheim, Celgene, Chugai, Kyowa Hakko Kirin, Merck Sharp & Dohme, Merck Serono, Novartis, Pfizer, Regeneron, Sanofi-Aventis/Genzyme, Valeant.

- DT: Research support/principal investigator (clinical trials): AbbVie, Almirall, Amgen, Baxter, Biogen Idec, Boehringer Ingelheim, Celgene, Coherus, Eli Lilly, Forward Pharma, Galderma, GlaxoSmithKline, Janssen, Kyowa Hakko Kirin, Leo, Mylan, Novartis, Pfizer, Regeneron, Roche, Sanofi-Aventis/Genzyme, Takeda, UCB, Valeant.

- KG: Grant support and consulting fees: AbbVie, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Eli Lilly, Janssen, Novartis, UCB; Consulting fees: AbbVie, Almirall, Amgen, Baxter, Biogen Idec, Boehringer Ingelheim, Celgene, Coherus, Eli Lilly, Forward Pharma, Galderma, Genentech, GlaxoSmithKline, Janssen, Kyowa Hakko Kirin, Leo, Mylan, Novartis, Pfizer, Regeneron, Roche, Sanofi-Aventis/Genzyme, Takeda, UCB, Valeant.

- KY: Grant support and consulting fees: AbbVie, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Eli Lilly, Janssen, Novartis, UCB; Consulting fees: AbbVie, Almirall, Amgen, Baxter, Biogen Idec, Boehringer Ingelheim, Celgene, Coherus, Eli Lilly, Forward Pharma, Galderma, Genentech, GlaxoSmithKline, Janssen, Kyowa Hakko Kirin, Leo, Mylan, Novartis, Pfizer, Regeneron, Roche, Sanofi-Aventis/Genzyme, Takeda, UCB, Valeant.

- PF: Consulting fees: AbbVie, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Eli Lilly, Janssen, Novartis, UCB; Research support: AbbVie, Almirall, Amgen, Baxter, Biogen Idec, Boehringer Ingelheim, Celgene, Coherus, Eli Lilly, Forward Pharma, Galderma, Genentech, GlaxoSmithKline, Janssen, Kyowa Hakko Kirin, Leo, Mylan, Novartis, Pfizer, Regeneron, Roche, Sanofi-Aventis/Genzyme, Takeda, UCB, Valeant.